These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 16760950)

  • 1. Biochemist strikes gold.
    Wadman M
    Nature; 2006 Jun; 441(7094):689. PubMed ID: 16760950
    [No Abstract]   [Full Text] [Related]  

  • 2. Companies eye slice of age-related macular degeneration market.
    Waltz E
    Nat Biotechnol; 2006 Sep; 24(9):1041-2. PubMed ID: 16964195
    [No Abstract]   [Full Text] [Related]  

  • 3. More than meets the eyes?
    Jacobs T
    Nat Biotechnol; 2004 Oct; 22(10):1221. PubMed ID: 15470455
    [No Abstract]   [Full Text] [Related]  

  • 4. Regeneron focuses on age-related macular degeneration.
    Wolfson W
    Chem Biol; 2008 Apr; 15(4):303-4. PubMed ID: 18420133
    [No Abstract]   [Full Text] [Related]  

  • 5. Deal watch: Alcon licenses complement pathway inhibitor for macular degeneration.
    Nat Rev Drug Discov; 2009 Dec; 8(12):922. PubMed ID: 19949394
    [No Abstract]   [Full Text] [Related]  

  • 6. Oligo oligarchy-the surprisingly small world of aptamers.
    Thiel K
    Nat Biotechnol; 2004 Jun; 22(6):649-51. PubMed ID: 15175673
    [No Abstract]   [Full Text] [Related]  

  • 7. Opening up the Ivory Tower.
    Wilan KH
    Cell; 2007 Jun; 129(5):847-50. PubMed ID: 17540161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. California dreaming.
    Nature; 2007 Jul; 448(7152):388. PubMed ID: 17653147
    [No Abstract]   [Full Text] [Related]  

  • 9. With $1.6M award, biochemist tackles diabetes.
    Orenstein D
    R I Med J (2013); 2014 Feb; 97(2):59-60. PubMed ID: 24960867
    [No Abstract]   [Full Text] [Related]  

  • 10. Gene goldrush splits Harvard, worries brokers.
    Wade N
    Science; 1980 Nov; 210(4472):878-9. PubMed ID: 6933694
    [No Abstract]   [Full Text] [Related]  

  • 11. California campuses resist industry restrictions.
    Check E
    Nature; 2007 Jul; 448(7152):394-5. PubMed ID: 17653150
    [No Abstract]   [Full Text] [Related]  

  • 12. Chemical Biology Consortium Sweden.
    Hammarström LG; Jensen AJ
    ACS Chem Biol; 2013 Dec; 8(12):2605-6. PubMed ID: 24354290
    [No Abstract]   [Full Text] [Related]  

  • 13. Technology transfer is all about bringing in money.
    Richards WG
    Nature; 2006 Jun; 441(7094):690. PubMed ID: 16760952
    [No Abstract]   [Full Text] [Related]  

  • 14. Industry and medicine: conflicting interests and the power of money.
    Popovsky MA; Garcia N
    Transfusion; 2007 Jun; 47(6):1098-9. PubMed ID: 17524103
    [No Abstract]   [Full Text] [Related]  

  • 15. Industry and academics: losses no worry to Boston.
    Shulman S
    Nature; 1990 Jan; 343(6255):201. PubMed ID: 2300158
    [No Abstract]   [Full Text] [Related]  

  • 16. Biotech round the world: focus on Canada.
    Biotechnol J; 2008 Jul; 3(7):848-51. PubMed ID: 18624341
    [No Abstract]   [Full Text] [Related]  

  • 17. Reinventing tech transfer.
    Huggett B
    Nat Biotechnol; 2014 Dec; 32(12):1184-91. PubMed ID: 25489831
    [No Abstract]   [Full Text] [Related]  

  • 18. Basic drug research in universities and industry.
    Black J
    Br J Clin Pharmacol; 1986; 22 Suppl 1(Suppl 1):5S-7S. PubMed ID: 3567032
    [No Abstract]   [Full Text] [Related]  

  • 19. Biotech patents-business as usual?
    Lawrence S
    Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861
    [No Abstract]   [Full Text] [Related]  

  • 20. New ocular therapeutics: a view from the patenting perspective.
    Mucke HA
    IDrugs; 2007 Jan; 10(1):37-41. PubMed ID: 17187313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.